Actionable news
All posts from Actionable news
Actionable news in AGIO: Agios Pharmaceuticals, Inc.,

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

The first targeted blood cancer drug from Agios Pharmaceuticals (AGIO) will be submitted for approval in the U.S. by the end of the year, faster than investors expected.

Celgene (CELG) , which owns the rights to the Agios drug, known as AG-221, under an existing partnership, will be in charge of filing the new drug application for the treatment of patients with relapsed or refractory acute myeloid leukemia, or AML, caused by a mutated protein known as IDH2.

Agios disclosed the AG-221 approval submission plan...